Nike China Strategy to Lift Margins Despite $1 Billion Sales Hit, Bernstein Says 
Colgate-Palmolive Reaffirms 2026 Sales Outlook Despite Weak North America Demand 
Meta-backed research finds exposure to ‘untrustworthy’ social media is rare. The fine print is less reassuring 
Sony Eyes $1.3 Billion Tamron Acquisition as Lens Maker Reviews Offer 
Meta Stock Drops After Earnings Miss as AI Spending and Legal Costs Weigh on Profit 
Chipotle Q2 Earnings Beat Expectations as Sales Growth Drives Higher 2026 Outlook 
Apple Stock Slides 7% as Weak Sales Forecast Overshadows Quarterly Earnings Beat 
SpaceX Wins $1.6 Billion U.S. Space Force Launch Contracts for Falcon 9 Missions Through 2027 
Tesla Weighs China Business Separation Amid SpaceX Merger Speculation 
Holcim Raises 2026 Outlook After Strong Q2 Earnings Beat 
Samsung Q2 Profit Surges on AI Memory Chip Demand, Forecasts Strong Second Half 
Apple Q3 Earnings Beat as Record iPhone Sales Offset Services, China Weakness 
Arm Holdings Q1 Earnings Beat Estimates, Strong Q2 Outlook Fails to Lift ARM Stock 
WestJet Cancels 86 Flights as CUPE Strike Threat Disrupts Travel 
Sony Raises Full-Year Outlook After Q1 Profit Jumps 40% on Gaming and Chip Growth 
Capital One Says AML Review Led to Closure of Trump Organization Accounts 
Japan Earthquake Disrupts Auto and Chip Supply Chains 
RANCHO CORDOVA, Calif., April 25, 2018 -- Cesca Therapeutics Inc. (“Cesca” or the “Company”) (NASDAQ:KOOL) today announced that the Company will be exhibiting its full suite of cellular processing solutions, including CAR-TXpress™ for the semi-automated manufacture of CAR-T cell therapies, X-BACS™ for cell isolation and other X-Series™ kits, at the following cell therapy conferences in May:
- International Society of Cellular Therapy 2018 Annual Meeting
May 2 – 5, 2018
Booth: 322
Palais des congrès de Montréal
1001, Place Jean-Paul-Riopelle
Montreal, Canada
For more information: www.isct2018.com
- American Society of Gene and Cell Therapy 2018 Annual Meeting
May 16 – 19, 2018
Booth: 417
Hilton Chicago
720 South Michigan Avenue
Chicago, IL 60605
For more information: www.asgct.org/meetings-workshops/annual-meeting
- Phacilitate Automation Special Interest Group 2018
May 30 – 31, 2018
The Grove
Chandler’s Cross,
Watford WD3 4TG, Hertfordshire
London, UK
For more information: www.phacilitateautomation.com
About Cesca Therapeutics Inc.
Cesca Therapeutics develops, commercializes and markets a range of automated technologies for CAR-T and other cell-based therapies. Its device division, ThermoGenesis, provides a full suite of solutions for automated clinical biobanking, point-of-care applications, and automation for immuno-oncology. The Company is developing an automated, functionally-closed CAR-TXpress™ platform that addresses the critical unmet need for better cellular manufacturing and controls for the emerging CAR-T immunotherapy market. Cesca is an affiliated company of China-based Boyalife Group.
Company Contact:
Cesca Therapeutics Inc.
Wendy Samford
916-858-5191
[email protected]
Investor Contact:
Rx Communications
Paula Schwartz
917-322-2216
[email protected]
